Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma

Stopped early · Phase 1

Conditions studied: Glioblastoma

In brief

The goal of this single arm Phase I feasibility study is to investigate the tolerability of cannabis with concurrent chemoradiation in the treatment of glioblastoma multiforme (GBM). A strain of cannabis provided by The National Institute of Drug Abuse (NIDA) that has a high concentration of cannabidiol (CBD) and a low concentration of THC (relative to average street cannabis) will be tested in order to maximize clinical efficacy while minimizing intoxicating side effects in this medically-ill population.

Key facts

Study ID
NCT03246113
Run by
New York State Psychiatric Institute
People needed
1
Starts
2018-03-19
Expected to finish
2019-05-09
Last updated by the study team
2019-08-13

Who can join

Age: 21 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.